CAJ | 학술논문

目的：建立基于微流控细胞芯片技术分析CD14+单核细胞髓过氧化物酶（Myeloperoxidase，MPO）的方法，初步探讨急性粒-单核细胞白血病（M4）患者CD14+单核细胞的MPO表达。方法：以聚二甲基硅氧烷（PDMS）为基质材料，二次模塑成型工艺制备微流控细胞芯片。选取临床诊断M4患者48例，骨髓象大致正常患者52例作为对照组。设定微流控芯片检测单核细胞MPO方法，测定细胞MPO阳性率和程度。应用微流控细胞芯片法分析M4患者和对照组CD14+单核细胞的MPO表达。结果：设计微流控单细胞分析芯片，粒细胞能够进入相应微流控通道，可分离血细胞，但是白细胞周围存在影形细胞现象，而细胞形态未见有明显改变。M4患者骨髓细胞CD14+单核细胞MPO阳性率和活性明显高于对照组（P<0.05）。结论：应用微流控单细胞技术分析CD14+单核细胞MPO表达，结果显示M4患者CD14+单核细胞MPO活性明显高于对照组，有可能作为辅助检查标志物。
목적：건립기우미류공세포심편기술분석CD14+단핵세포수과양화물매（Myeloperoxidase，MPO）적방법，초보탐토급성립-단핵세포백혈병（M4）환자CD14+단핵세포적MPO표체。방법：이취이갑기규양완（PDMS）위기질재료，이차모소성형공예제비미류공세포심편。선취림상진단M4환자48례，골수상대치정상환자52례작위대조조。설정미류공심편검측단핵세포MPO방법，측정세포MPO양성솔화정도。응용미류공세포심편법분석M4환자화대조조CD14+단핵세포적MPO표체。결과：설계미류공단세포분석심편，립세포능구진입상응미류공통도，가분리혈세포，단시백세포주위존재영형세포현상，이세포형태미견유명현개변。M4환자골수세포CD14+단핵세포MPO양성솔화활성명현고우대조조（P<0.05）。결론：응용미류공단세포기술분석CD14+단핵세포MPO표체，결과현시M4환자CD14+단핵세포MPO활성명현고우대조조，유가능작위보조검사표지물。
Objective:A method that is based on microfluidic cell chip technology was developed for the first time to analyze CD14+monocyte myeloperoxidase (MPO) expression in myelomonocytic leukemia (M4) patients. CD14+monocyte MPO expression in M4 patients was preliminarily discussed. Methods:a. The chip was prepared by using polydimethylsiloxane as the host material and by secondary foam molding. b. A total of 48 clinically diagnosed M4 patients and 52 patients with normal myelogram were included as the test and control groups, respectively. c. A method based on the microfluidic cell chip approach was established to detect CD14+mono-cytes and to determine the positive rate and degree of MPO expression in the cells. d. The microfluidic cell chip technique was used to compare CD14+monocyte MPO expression in M4 patients with that in the control. Results:a. The designed microfluidic single cell analysis chip allowed the entry of granulocytes into the corresponding microfluidic channels. Thus, blood cells were separated. Numer-ous ghost corpuscles surrounded the separated white blood cells (WBCs). WBC morphology did not show obvious changes. b. The posi-tive rate of MPO expression and the activity of CD14+monocytes in the bone marrow of M4 patients were significantly higher than those in the bone marrow of the control (P<0.05). Conclusion:A method based on microfluidic single cell technology was developed for the first time to analyze the MPO expression in CD14+monocytes. CD14+monocyte MPO activity in M4 patients was significantly higher than in the control. CD14+monocyte MPO activity can be used as an auxiliary examination marker for clinical diagnosis.